HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men
HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men: A Randomized, Placebo-Controlled, Double-Blind Parallel Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Michael Furian, Prof. Dr.
- Phone Number: +41794037586
- Email: michael.furian@usz.ch
Study Contact Backup
- Name: Talant M Sooronbaev, Prof. Dr.
- Phone Number: +996772574567
- Email: sooronbaev@yahoo.ru
Study Locations
-
-
Gorod Bishkek
-
Bishkek, Gorod Bishkek, Kyrgyzstan, 720040
- National center for cardiology and internal medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy, non-smoking men and women, age 18-44 years, without any disease and need of regular medication (including oral contraceptives).
- BMI >18 kg/m2 and <30 kg/m2
- Born, raised and currently living at altitudes <1000 m
- Written informed consent
- Premenopausal women with an eumenorrheic cycle
Exclusion Criteria:
- Other types of contraceptvies (contraceptives (hormonal intrauterine device, vaginal ring, subcutaneous injections or implants, among others)
- Pregnancy or nursing
- Anaemic (haemoglobin concentration <10g/dl)
- Any altitude trip <4 weks before the study
- Allergy to acetazolamide and other sulfonamides
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: WOMEN - ACETAZOLAMIDE oral capsule
Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally.
Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
|
Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
|
|
Active Comparator: MEN - ACETAZOLAMIDE oral capsule
Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally.
Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
|
Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
|
|
Placebo Comparator: WOMEN - PLACEBO oral capsule
Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally.
Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
|
Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
|
|
Placebo Comparator: MEN - PLACEBO oral capsule
Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally.
Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
|
Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute Mountain Sickness (AMS) Incidence, LLS 2018
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related difference between acetazolamide and placebo group in the incidence of AMS.
AMS incidence will be defined as a Lake Louise Questionnaire version 2018 score of ≥3.
|
Day 1 to 3 at 3600 m
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute Mountain Sickness (AMS) Incidence, LLS 1993
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related difference between acetazolamide and placebo group in the incidence of AMS.
AMS incidence will be defined as a Lake Louise Questionnaire version 1993 score of ≥3.
|
Day 1 to 3 at 3600 m
|
|
Acute Mountain Sickness (AMS) Severity, LLS 2018
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related difference between acetazolamide and placebo group in the AMS severity assessed by the Lake Louise Questionnaire version 2018.
|
Day 1 to 3 at 3600 m
|
|
Acute Mountain Sickness (AMS) Severity, LLS 1993
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related difference between acetazolamide and placebo group in the AMS severity assessed by the Lake Louise Questionnaire version 1993.
|
Day 1 to 3 at 3600 m
|
|
Drug-related side effects
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related difference between acetazolamide and placebo group in the incidence and severity of medication side effects.
|
Day 1 to 3 at 3600 m
|
|
Arterial blood gases
Time Frame: Day 2 at 760 m and day 2 at 3600 m
|
Sex-related differences between acetazolamide and placebo group in the arterial blood gases (pH, PaO2, PaCO2, SaO2).
|
Day 2 at 760 m and day 2 at 3600 m
|
|
Acetazolamide plasma concentration
Time Frame: Day 2 at 3600 m
|
Sex-related differences between acetazolamide plasma concentration assessed by dried blood spots.
|
Day 2 at 3600 m
|
|
Hypoxic ventilatory response
Time Frame: Day 2 at 760 m
|
Sex-related difference in the hypoxic ventilatory response assessed under FiO2 of 0.115 and while cycling on a bicycle at 30% of predicted maximal work capacity.
|
Day 2 at 760 m
|
|
Perceived pain visualization
Time Frame: Day 1 to 3 at 3600 m
|
Sex-related differences between acetazolamide and placebo group on perceived pain sensations, visualized by the SMaRT tablet app
|
Day 1 to 3 at 3600 m
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Michael Furian, Prof. Dr., University of Zurich
- Study Director: Talant Sooronbaev, Prof. Dr., National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Signs and Symptoms, Respiratory
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Hypoxia
- Altitude Sickness
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Thiazoles
- Azoles
- Thiadiazoles
- Acetazolamide
Other Study ID Numbers
Other Study ID Numbers
- HighCycle_AMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.